Highly prevalent TERT promoter mutations in aggressive thyroid cancers
نویسندگان
چکیده
منابع مشابه
Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Mutations 1 295 228 C>T and 1 295 250 C>T (termed C228T and C250T respectively), corresponding to -124 C>T and -146 C>T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene, have recently been reported in human cancers, but not in thyroid cancers yet. We explored these mutations in thyroid cancers by genomic sequencing of a large number of primary ...
متن کاملTERT Promoter Mutations in Thyroid Cancer.
Two mutations (C228T and C250T) in the promoter region of the telomerase reverse transcriptase (TERT) have recently been described in different types of cancer including follicular cell-derived thyroid cancer (TC). In this paper, we reviewed the rates of these mutations in different types and subtypes of TC, their association with a number of clinical and histopathological features and outcome ...
متن کاملFrequency of TERT promoter mutations in human cancers.
Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (w...
متن کاملHigh frequency of TERT promoter mutations in human cancers
Reactivation of telomerase has been implicated in human tumourigenesis, but the underlying mechanisms remain poorly understood. Here, we report the presence of recurrent somatic mutations in TERT promoter in cancers of the central nervous system, (43%), bladder (59%), thyroid (follicular cell-derived) (10%) and skin (melanoma, 29%). We also show that, in central nervous system and thyroid cance...
متن کاملAggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of advanced differentiated thyroid carcinoma (DTC). Resistance to sorafenib may appear under treatment and may be associated with increased aggressiveness of the neoplasia. The present study reports the case of a 65-year-old male who underwent total thyroidectomy for a follicular thyroid carcinoma, Hürthle cell variant, in Fe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrine-Related Cancer
سال: 2013
ISSN: 1351-0088,1479-6821
DOI: 10.1530/erc-13-0210